I have some musings, questions and points of clarification I'd like to post and it will be a one-time thing, as I'm leery of IHub and some snakes that slither around in front of, and behind the scenes.
First, as to Mastascope, Ovascope, etc. recently mentioned - those were parts of First Warning Systems back in the early 2000's. The article that was brought up, although it gave a current date of re-posting, can actually be seen in the PR as a publishing date in 2005. Those entities were spun off as Solos Endoscopy in 2006, I believe, and until July of 2017, I used to have restricted shares of that spin-off, or whatever it was, from 2006. It was SOLOS/SOLO. I could never do anything with them and when this article was brought up, I looked at my Scottrade account and see that on July 13, 2017, a mystery number of shares for SOLO was delivered out, I was charged a $20 reorg fee and ?? shares of SNDY was received. It isn't listed on my portfolio, though, and it makes me wonder if things were being cleaned up or if there is something going on with that entity.
Secondly, people like PenBlanc like to comment that no news or updates have been provided on the Lifeline website for years but, while frustrating, current news or filings should be sought out on OTC Markets, where you will find that they are current and updated as required for a pink sheet stock, up to and including last year.
I always wonder, also, why people pretend that Lifeline and Cyrcadia are some competing businesses trying to screw each other. Have you ever simply looked up the physical addresses of both and who the players are? They are basically interchangeable, including Jim Holmes active in both and his son, Matt Bernardis, on Cyrcadia. The only reason for creating Cyrcadia, with its private financing, was to raise needed money and not dilute Lifeline stock further - a bunch of red tape juggling. To say Cyrcadia is trying to steal Lifeline shareholder value is comical - and there is the 45-plus-percent stake that we, as Lifeline holders, have in Cyrcadia's success.
Speaking of the deal with Cyrcadia Asia as "peanut" value, you should see that starting in Asia - with less regulatory restrictions and giant potential market - as the pilot program, it will speed up the US launch and FDA clearances. They are also funding costs and manufacturing, and providing 2-percent interest for us, while also funneling funds to pay off debt through Cyrcadia U.S. to Lifeline. If viewed properly, it should be seen as a pretty savvy move.
As far as FDA approval, Lifeline - or now, Cyrcadia - already has Class II FDA clearance, which allows them to sell through physicians. They are seeking a non-filing Class I to allow over-the-counter sales. Either way, they are cleared to sell in the U.S. now and success in Asia should fast-track the Class I approval.
I may not have everything perfectly correct but I have enough confidence to turn down the noise of the negative last-gasp talk by some. This will be the year that makes or breaks the technology, since the capability and times seem to be merged at this point. I hope PenBlanc has a GTC ask for .0038 for every last share he has. In that case, there may be tears shed for that same block he's been lamenting being stuck with when they actually leave his account. We'll see.
Okay. That's my two cents and first/final post. Just needed to vent a little... :)